Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 33,125	$ 13,423	$ 57,614	$ 24,768
General and administrative	9,067	3,541	16,503	6,257
Total operating expenses	42,192	16,964	74,117	31,025
Loss from operations	(42,192)	(16,964)	(74,117)	(31,025)
Other income (expense):
Change in fair value of antidilution rights liability	0	(25,970)	0	(25,574)
Change in fair value of success payment liability	938	(10,036)	2,615	(9,654)
Interest and other income, net	308	5	390	25
Total other income (expense), net	1,246	(36,001)	3,005	(35,203)
Net loss	$ (40,946)	$ (52,965)	$ (71,112)	$ (66,228)
Net loss per common share attributable to common stockholders, basic and diluted	$ (0.84)	$ (6.66)	$ (1.46)	$ (12.46)
Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted	48,674,873	7,948,110	48,623,330	5,316,084
Comprehensive Loss:
Net loss	$ (40,946)	$ (52,965)	$ (71,112)	$ (66,228)
Other comprehensive loss:
Unrealized loss on marketable securities	(206)	(4)	(710)	(5)
Comprehensive loss	$ (41,152)	$ (52,969)	$ (71,822)	$ (66,233)